LAG3 and classic Hodgkin lymphoma: A clinical study investigating the preliminary efficacy of the anti-LAG-3 monoclonal antibody BMS-986016 in combination with nivolumab in relapsed or refractory cHL is currently ongoing (clinicaltrials.gov identifier: 02061761).